TCGA-80-5611-01A-01R-1628-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.580
- E2F_TARGETS+0.460
- INTERFERON_GAMMA_RESPONSE+0.460
- OXIDATIVE_PHOSPHORYLATION+0.450
- G2M_CHECKPOINT+0.350
- ALLOGRAFT_REJECTION+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
- MYC_TARGETS_V1+0.300
- FATTY_ACID_METABOLISM+0.280
- IL6_JAK_STAT3_SIGNALING+0.280
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- ANGIOGENESIS-0.410
- PANCREAS_BETA_CELLS-0.360
- HEDGEHOG_SIGNALING-0.320
- MYOGENESIS-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- APICAL_SURFACE-0.270
- KRAS_SIGNALING_DN-0.270
- TGF_BETA_SIGNALING-0.270
- APICAL_JUNCTION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG487 | — | — | 0.865 |
| 2 | SRR5088813 | — | — | 0.859 |
| 3 | GSM6454734 | — | D | 0.859 |
| 4 | BS_W80TJC27 | EPN | Supratentorial EPN | 0.858 |
| 5 | 5ffcc7c5-661f-4eed-b5e6-ed158c668321 | — | — | 0.857 |
| 6 | R371 | — | — | 0.854 |
| 7 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.851 |
| 8 | MNG477 | — | — | 0.851 |
| 9 | TCGA-BH-A0EE-01A-11R-A034-07 | — | C | 0.851 |
| 10 | 20070130.TNBC | — | C | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |